Bone Health Lifetime Challenges

Considerations  in the use of antiresorptive agents, new treatment options, and a call to  action

  In the previous two installments of our Bone Health  Lifetime Challenge series on issues surrounding bone mass accrual and  osteoporosis in older adult fragility fracture patients, we addressed, in part  one, nutrition, supplementation, and activity, and in part two, diagnosis and  treatment. Here in part three, we discuss two potential adverse reactions to  antiresorptive agents. Most commonly, these have been reported in studies of  long-term bisphosphonate (BP) use. We conclude with a call for efforts to close  the osteoporosis treatment gap, with orthopaedic surgeons taking the lead in  promoting the bone health of all of our patients and the population at large.

This content is only available to members of the AAOS.

Please log in using the link at the top right corner of this page to access your exclusive AAOS member content.

Not a member? Become a member!

Advertisements


Advertisement